Visiongain Publishes Real-World Evidence (RWE) Solutions Market Report 2020-2030

02 October 2020
Pharma

Visiongain has published a new report on Real-World Evidence (RWE) Solutions Market Report 2020-2030: Forecasts by Component (Data Sets, Services), Datasets (Clinical Settings Data, Claims Data, Pharmacy Data, Patient-Powered Data, Others), Therapeutic Area (Oncology, Cardiovascular Diseases, Neurology, Immunology, Other Therapeutic Areas), End-users (Healthcare Payers, Healthcare Providers, Pharmaceutical & Medical Device Companies, Other End-users), by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), PLUS COVID-19 Recovery Scenarios and Profiles of Leading Real-World Evidence Solutions Companies.

This report evaluates the real-world evidence market for the period, 2020-2030. The global market is estimated to be worth US$ xx million in 2020 and is projected to reach US$ xx million in 2030 while growing at a CAGR of xx% over the forecast period from 2020 to 2030.

COVID-19 Impact on Real-World Evidence Market
The COVID pandemic has impacted this market in a very positive way. There is no such cure for the disease and the vaccines are still in development and trial stages. With the use of real-world evidence (RWE) solutions, the data present is expected to give out positive results. Numerous large vaccine trials have been launched to study the effects on coronavirus, which includes around 30,000 volunteers for most of the trials. But such clinical trials are not capable of offering all the data required by scientists in their pursuit to tame the COVID-19 pandemic. The COVID-19 pandemic has added an urgency to use real-world evidence (RWE) solutions, boosting the market in the coming years. It’s a global scale health crisis, patient records collected every hour can be analyzed and used to offer a better picture of the COVID-19 pandemic.

Market Drivers

Increasing use of Bigdata in Healthcare Industry
Real-world studies and real-world evidence are gradually becoming significant in offering confirmation and data for effective cure and treatment during clinical practice and trials. Real-world studies use information from electronic health records and claims databases, which offer large datasets from varied patient populations, and are also collecting observational, retrospective, or prospective data from a long time period. They also offer information on the long-term use and safety of drugs mainly relating to rare events, and efficacy of drugs in huge diverse populations, and economic outcomes. Growing use of Bigdata and various algorithms have helped hospitals in the management of many chronic conditions by creating similar construction of algorithms that can codify the management of these conditions. This offers efficient and rapid management of the condition with improved patient experience and a scalable solution that can reduce the burden on primary care physicians.

Market Opportunities

Long-Term Outlook for Chronic Disease Management
The continuous strong growth in the chronic disease management therapeutics and device technologies is expected to create new opportunities for using real world evidence solutions. There will always be a need for safe and effective therapeutics to more efficiently manage chronic diseases, but the future of the chronic disease management market is not solely dependent upon innovative drugs and biologics. Technological advancements in continuous and remote disease monitoring may reduce the overall cost burden of chronic diseases with improved treatment adherence. New investments in R&D activities, advancements in wearable monitoring and drug delivery are also expected to set new milestones for surgeons and patients. Prophylactic management of the disease, including the adoption of healthier lifestyles, represents great progress and reduces the overall burden of chronic diseases.

Competitive Landscape
Some of the companies profiled in the report include Iqvia, IBM, Pharmaceutical Product Development, PAREXEL, Optum (A Subsidiary of United Health Group, Inc.), PerkinElmer, Icon PLC, Oracle, Cognizant, Syneos Health, Anthem, Clinigen, and Covance Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Pharmaceutical Product Information Management System Market Report 2020-2030

Some of the major factors fuelling the growth of global market include significant advantages associated with PIM solutions and inclination towards centralized models among across pharma sector.

19 October 2020

Read

Visiongain Publishes Pulmonary/Respiratory Drug Delivery Market Report 2020-2030

The coronavirus outbreak has negatively impacted all the economies and industries across the globe. Hence, for the next 1-2 years, the global respiratory drug delivery market is expected to take a hit.

12 October 2020

Read

Visiongain Publishes Real-World Evidence (RWE) Solutions Market Report 2020-2030

We predict strong revenue growth through to 2030. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

02 October 2020

Read

Visiongain Publishes mRNA Vaccines Market Report 2021-2031

The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative vaccine formats like mRNA preventive boost, and new molecular adjuvant technologies are particularly important for mRNA vaccines reaching their potential.

02 October 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever